SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021517
Filing Date
2023-05-12
Accepted
2023-05-12 08:47:47
Documents
49
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q labp-20230331.htm   iXBRL 10-Q 1285172
2 EX-10.1 labp-ex10_1.htm EX-10.1 205270
3 EX-31.1 labp-ex31_1.htm EX-31.1 27578
4 EX-32.1 labp-ex32_1.htm EX-32.1 16717
  Complete submission text file 0000950170-23-021517.txt   5286791

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20230331_lab.xml EX-101.LAB 343528
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT labp-20230331_cal.xml EX-101.CAL 33344
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20230331.xsd EX-101.SCH 35746
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20230331_pre.xml EX-101.PRE 241325
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT labp-20230331_def.xml EX-101.DEF 132618
43 EXTRACTED XBRL INSTANCE DOCUMENT labp-20230331_htm.xml XML 782310
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39971 | Film No.: 23913419
SIC: 2834 Pharmaceutical Preparations